Rebyota

Rebiotix, a subsidiary of Ferring Pharmaceuticals, is a clinical-stage biotechnology company pioneering the development of Microbiota Restoration Therapy (MRT) to treat challenging diseases by rehabilitating the human microbiome. The company's lead product, Rebyota (fecal microbiota, live-jslm), made history in 2022 as the first-ever FDA-approved fecal microbiota product, indicated for the prevention of recurrent Clostridioides difficile infection (CDI). Rebiotix's MRT platform utilizes a standardized, ready-to-use format to deliver a broad consortium of live, human-derived microbes to the patient's intestinal tract. Beyond CDI, the company is advancing a diverse pipeline targeting ulcerative colitis, hepatic encephalopathy, and multi-drug resistant organism decolonization. Founded in 2011 and acquired by Ferring in 2018, Rebiotix continues to lead the field in live biotherapeutic product (LBP) innovation.